Product Code: GVR-2-68038-700-1
The Asia Pacific biopharma excipients market size is poised to reach USD 791.4 million by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.63% during the forecast period. Patent expiry of blockbuster biologics such as Erbitux, Rituxan, Herceptin, Avastin, Aranesp, and Enbrel by 2030 is encouraging investments in biosimilars R&D by biopharma players. Soaring need for novel additives for development of biologics such as those enhancing lyophilization performance to improve stability of biologics is anticipated to boost the demand for excipients.
As per drug sales record of 2016, eight out of ten top-selling drugs are biologics. Upcoming patent expiry of biologics is leading to increased R&D for biosimilar formulations. Biopharma players in the market are adopting price reduction strategies in order to promote their products. This is triggering the need for consideration of pricing strategy among excipient manufacturers.
Presence of challenges in development of a stable form of biotherapeutic is urging manufacturers to develop novel excipients. Processing and storage of biomolecules are complicated as these products undergo degradation after a slight change in environmental conditions. Rising demand for chemicals that are compatible with these biomolecules and serve additional functions such as binding, bulking, and efficient delivery is stimulating the growth of the market. Technological advancements, such as implementation of nanotechnology in the development of novel compounds to enhance drug delivery, are likely to drive the market. For instance, an Australian provider of microencapsulation for drug delivery, Ceramisphere, expanded its operations for production of nanoparticles with extended-release capacity.
Furthermore, Asian countries such as India & China serve as major markets for biogenerics. Key pharmaceutical players in the market are increasing their R&D activities on follow-on-biologic. Biologics R&D is outsourced to CROs in the region as a consequence of cost efficiency provided by them, which is consequently boosting the demand for excipients.
Further key findings from the report suggest:
- Carbohydrates accounted the largest revenue share due to substantial product penetration in the market owing to higher availability of raw materials as well as easy molecular processing characteristics
- In terms of revenue, the polyols segment is projected to expand at a CAGR of 6.90% during the forecast period
- Japan dominated the market in terms of revenue. However, in terms of sale volume, the Japanese economy was not on the top as a consequence of high product pricing
- In February 2014, International Pharmaceutical Excipients Council of India (IPEC) was launched. Leading international pharmaceutical companies are founder members of this council, which includes Dow Chemicals, Lubrizol, BASF, SPI Pharma, Colorcon, Indchem International. It is estimated to assist the government of India in evolving direction, standards, and development of the excipient industry in the country, thus working in favor of the market
- In August 2016, China FDA announced to review excipients as a part of new drug application. The former system considered separate review approvals for a drug, its excipient, and its active ingredient.
Some key companies present in the market are: Roquette, DFE Pharma, Pharmonix, Spectrum Chemical Manufacturing Corp., IMCD, Clariant, Signet Chemical Corporation Pvt. Ltd., Sigachi Industries Pvt. Ltd., ABITEC, Colorcon, Meggle AG, SPI Pharma, and BASF SE.
Table Of Contents
Chapter 1: Executive Summary
Chapter 2: Research Methodology
- 2.1 Information procurement
- 2.1.1 Purchased database:
- 2.1.2 GVR's Internal Database
- 2.2 Information or Data Analysis
- 2.3 Market Formulation & Validation
- 2.4 Approaches for Market Estimation
- 2.4.1 Approach 1: Commodity flow & bottom up approach
- 2.4.2 Approach 2: Top down and parent market analysis
Chapter 3: Asia Pacific Biopharma Excipients Market Variables, Trends& Scope
- 3.1 Market Segmentation &Scope
- 3.1.1 Market driver analysis
- 3.1.1.1 Need for novel excipients in biologics/biosimilars development
- 3.1.1.2 Increasing focus of pharma players on biogeneric market
- 3.1.1.3 Cost-efficiency and competency of manufacturers
- 3.1.1.4 Patent expiry of biological actives
- 3.1.2 Market restraint analysis
- 3.1.2.1 Challenges in development of excipients for biologics
- 3.1.2.2 Problems in supply chain
- 3.1.2.3 Patent challenges and disputes over biosimilars
- 3.2 Penetration & Growth Prospect Mapping for Products, 2017
- 3.3 Biopharma Excipients Market-SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
- 3.4 Industry Analysis - Porter's
Chapter 4: Asia Pacific Biopharma Excipients Market Categorization: Product Estimates & Trend Analysis
- 4.1 Asia Pacific Biopharma Excipients Market: Product Movement Analysis
- 4.2 Solubilizers & Surfactants/Emulsifiers
- 4.2.1 Asia Pacific solubilizers & surfactants/emulsifiers market, by revenue 2014 - 2025 (USD Million)
- 4.2.2 Asia Pacific solubilizers & surfactants/emulsifiers market, by volume 2014 - 2025 (Tons)
- 4.2.3 Triglycerides
- 4.2.3.1 Asia Pacific triglycerides market, by revenue 2014 - 2025 (USD Million)
- 4.2.3.2 Asia Pacific triglycerides market, by volume 2014 - 2025 (Tons)
- 4.2.4 Esters
- 4.2.4.1 Asia Pacific esters market, by revenue 2014 - 2025 (USD Million)
- 4.2.4.2 Asia Pacific esters market, by volume by 2014 - 2025 (Tons)
- 4.2.5 Other solubilizer
- 4.2.5.1 Asia Pacific other solubilizers market, by revenue 2014 - 2025 (USD Million)
- 4.2.5.2 Asia Pacific other solubilizers market, by volume 2014 - 2025 (Tons)
- 4.3 Polyols
- 4.3.1 Asia Pacific polyols market, by revenue 2014 - 2025 (USD Million)
- 4.3.2 Asia Pacific polyols market, by volume 2014 - 2025 (Tons)
- 4.3.3 Mannitol
- 4.3.3.1 Asia Pacific mannitol market, by revenue 2014 - 2025 (USD Million)
- 4.3.3.2 Asia Pacific mannitol market, by volume 2014 - 2025 (Tons)
- 4.3.4 Sorbitol
- 4.3.4.1 Asia Pacific sorbitol market, by revenue 2014 - 2025 (USD Million)
- 4.3.4.2 Asia Pacific sorbitol market, by volume 2014 - 2025 (Tons)
- 4.3.5 Other polyols
- 4.3.5.1 Asia Pacific other polyols market, by revenue 2014 - 2025 (USD Million)
- 4.3.5.2 Asia Pacific other polyols market, by volume 2014 - 2025 (Tons)
- 4.4 Carbohydrates
- 4.4.1 Asia Pacific carbohydrates market, by revenue 2014 - 2025 (USD Million)
- 4.4.2 Asia Pacific carbohydrates market, by volume 2014 - 2025 (Tons)
- 4.4.3 Dextrose
- 4.4.3.1 Asia Pacific dextrose market, by revenue 2014 - 2025 (USD Million)
- 4.4.3.2 Asia Pacific dextrose market, by volume 2014 - 2025 (Tons)
- 4.4.4 Sucrose
- 4.4.4.1 Asia Pacific sucrose market, by revenue 2014 - 2025 (USD Million)
- 4.4.4.2 Asia Pacific sucrose market, by volume 2014 - 2025 (Tons)
- 4.4.5 Starch
- 4.4.5.1 Asia Pacific starch market, by revenue 2014 - 2025 (USD Million)
- 4.4.5.2 Asia Pacific starch market, by volume 2014 - 2025 (Tons)
- 4.4.6 Others
- 4.4.6.1 Asia Pacific other carbohydrates market, by revenue 2014 - 2025 (USD Million)
- 4.4.6.2 Asia Pacific other carbohydrates market, by volume 2014 - 2025 (Tons)
- 4.5 Specialty Biopharma Excipients/Others
- 4.5.1 Asia Pacific specialty biopharma excipients/others market, by revenue 2014 - 2025 (USD Million)
- 4.5.2 Asia Pacific specialty biopharma excipients/others market, by volume 2014 - 2025 (Tons)
Chapter 5: Asia Pacific Biopharma Excipients Market Categorization: Regional Estimates & Trend Analysis
- 5.1 Asia Pacific Biopharma Excipients Market: Regional Movement Analysis
- 5.2 Japan
- 5.2.1 Japan biopharma excipients market, by revenue 2014 - 2025 (USD Million)
- 5.2.2 Japan biopharma excipients market, by volume 2014 - 2025 (Tons)
- 5.3 China
- 5.3.1 China biopharma excipients market, by revenue 2014 - 2025 (USD Million)
- 5.3.2 China biopharma excipients market, by volume 2014 - 2025 (Tons)
- 5.4 India
- 5.4.1 India biopharma excipients market, by revenue 2014 - 2025 (USD Million)
- 5.4.2 India biopharma excipients market, by volume 2014 - 2025 (Tons)
- 5.5 Malaysia
- 5.5.1 Malaysia biopharma excipients market, by revenue 2014 - 2025 (USD Million)
- 5.5.2 Malaysia biopharma excipients market, by volume 2014 - 2025 (Tons)
- 5.6 South Korea
- 5.6.1 South Korea biopharma excipients market, by revenue 2014 - 2025 (USD Million)
- 5.6.2 South Korea biopharma excipients market, by volume 2014 - 2025 (Tons)
- 5.7 Philippines
- 5.7.1 Philippines biopharma excipients market, by revenue 2014 - 2025 (USD Million)
- 5.7.2 Philippines biopharma excipients market, by volume 2014 - 2025 (Tons)
- 5.8 New Zealand
- 5.8.1 New Zealand biopharma excipients market, by revenue 2014 - 2025 (USD Million)
- 5.8.2 New Zealand biopharma excipients market, by volume 2014 - 2025 (Tons)
- 5.9 Australia
- 5.9.1 Australia biopharma excipients market, by revenue 2014 - 2025 (USD Million)
- 5.9.2 Australia biopharma excipients market, by volume 2014 - 2025 (Tons)
- 5.10 Singapore
- 5.10.1 Singapore biopharma excipients market, by revenue 2014 - 2025 (USD Million)
- 5.10.2 Singapore biopharma excipients market, by volume 2014 - 2025 (Tons)
- 5.11 Indonesia
- 5.11.1 Indonesia biopharma excipients market, by revenue 2014 - 2025 (USD Million)
- 5.11.2 Indonesia biopharma excipients market, by volume 2014 - 2025 (Tons)
Chapter 6: Competitive Landscape
- 6.1 Strategy Framework
- 6.2 Market Participation Categorization
- 6.3 Company Profiles
- 6.3.1 Merck KGaA
- 6.3.1.1 Company overview
- 6.3.1.1.1 Merck Millipore
- 6.3.1.2 Financial performance
- 6.3.1.3 Product benchmarking
- 6.3.1.4 Strategic initiatives
- 6.3.2 Signet Chemical Corporation Pvt. Ltd.
- 6.3.2.1 Company overview
- 6.3.2.2 Financial performance
- 6.3.2.3 Product benchmarking
- 6.3.2.4 Strategic initiatives
- 6.3.3 Sigachi Industries Pvt. Ltd.
- 6.3.3.1 Company Overview
- 6.3.3.2 Financial performance
- 6.3.3.3 Product benchmarking
- 6.3.3.4 Strategic initiatives
- 6.3.4 ABITEC
- 6.3.4.1 Company overview
- 6.3.4.2 Financial performance
- 6.3.4.3 Product benchmarking
- 6.3.4.4 Strategic initiatives
- 6.3.5 Spectrum Chemical Manufacturing Corp.
- 6.3.5.1 Company overview
- 6.3.5.2 Financial performance
- 6.3.5.3 Product benchmarking
- 6.3.5.4 Strategic initiatives
- 6.3.6 Roquette
- 6.3.6.1 Company overview
- 6.3.6.2 Financial performance
- 6.3.6.3 Product benchmarking
- 6.3.6.4 Strategic initiatives
- 6.3.7 IMCD
- 6.3.7.1 Company overview
- 6.3.7.1.1 Indchem International
- 6.3.7.2 Financial performance
- 6.3.7.2.1 Financial performance (Indchem International)
- 6.3.7.3 Product benchmarking
- 6.3.7.4 Strategic initiatives
- 6.3.8 Pharmonix
- 6.3.8.1 Company overview
- 6.3.8.2 Financial performance
- 6.3.8.3 Product benchmarking
- 6.3.8.4 Strategic initiatives
- 6.3.9 Clariant
- 6.3.9.1 Company overview
- 6.3.9.2 Financial performance
- 6.3.9.3 Product benchmarking
- 6.3.9.4 Strategic initiatives
- 6.3.10 DFE Pharma
- 6.3.10.1 Company overview
- 6.3.10.2 Financial performance
- 6.3.10.3 Product benchmarking
- 6.3.10.4 Strategic initiatives
- 6.3.11 Colorcon
- 6.3.11.1 Company overview
- 6.3.11.2 Financial performance
- 6.3.11.3 Product benchmarking
- 6.3.11.4 Strategic initiatives
- 6.3.12 SPI Pharma
- 6.3.12.1 Company overview
- 6.3.12.2 Financial performance
- 6.3.12.3 Product benchmarking
- 6.3.12.4 Strategic initiatives
- 6.3.13 JRS PHARMA
- 6.3.13.1 Company overview
- 6.3.13.2 Financial performance
- 6.3.13.3 Product benchmarking
- 6.3.13.4 Strategic initiatives
- 6.3.14 BASF SE
- 6.3.14.1 Company overview
- 6.3.14.2 Financial performance
- 6.3.14.3 Product benchmarking
- 6.3.14.4 Strategic initiatives
